Research ArticleVaccines

Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice

See allHide authors and affiliations

Science Translational Medicine  08 Jan 2020:
Vol. 12, Issue 525, eaav5701
DOI: 10.1126/scitranslmed.aav5701

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Do mother’s antibodies know best?

Infants are susceptible to many infections. One promising strategy to shield them is through vaccination of mothers during pregnancy, thus providing maternal antibodies that can temporarily protect infants from disease. However, maternal antibodies can also prevent infants from developing their own antibody responses that are necessary for long-term protection. Willis et al. now show that an influenza vaccine consisting of nucleoside-modified mRNAs encapsulated in lipid nanoparticles elicited protective antibodies in mouse pups in the presence of maternal antibodies. These authors show that, unlike conventional influenza vaccines, the mRNA vaccine is able to partially overcome the inhibitory effects of maternal antibodies in mouse pups.

View Full Text

Stay Connected to Science Translational Medicine